David J. Glass, Ph.D.
Selected Technology Transfer Agreements Negotiated

David J. Glass, in almost ten years experience at Massachusetts General Hospital and over 4 years working as a consultant, has negotiated a large number of academic/industry technology transfer agreements, including over 100 licenses and options and an equal number of sponsored research agreements, and including the following:

• Exclusive licenses for the founding technologies of several companies including Phylos, Inc., Biostream, Inc., Seacoast Technologies, Inc., VisEn, Inc., and others. Several of these licenses included equity awards to Mass. General Hospital.
• Sponsored research and license agreement for novel Alzheimer's Disease therapies, to found Prana Biotechnology, Inc., an Australian company.
• Several other license agreements forming new start-up companies, or conveying equity to Mass. General Hospital in early stage companies (e.g., Oxford BioMedica plc, DevGen, Inc., in the latter category).

Other Significant License Agreements

• Exclusive license to Sepracor, Inc. of McLean Hospital's joint interest in U.S. patents for the enantiomeric form of Prozac, subsequently sublicensed to Eli Lilly and Company in a major partnership for Sepracor.
• Exclusive license to QLT, Inc. of MGH's joint interest in a U.S. patent for photodynamic therapy of an ophthalmic disorder that is expected to be an $800 million annual market.
• Exclusive license of a portfolio of patent applications on C. elegans genes involved in diabetes/obesity to a European biotechnology company.
• Two exclusive licenses to a U.S. venture capital firm, to create companies focusing on gene therapy for cancer and to commercialize therapeutics for psychiatric disorders.
• Exclusive licenses to several gene therapy companies (U.S. and Europe) for novel vector technologies.
• Exclusive license to a medical laser company for a laser-based therapy for glaucoma and other ophthalmic disorders.
• Several licenses and options to a multinational agrichemical company for technology involving plant disease resistance genes.

Other Licenses: Molecular Biology, Biotechnology and Pharmaceuticals

• Exclusive license to a biotechnology-based diagnostics company for a nucleic acid amplification technology.
• Exclusive license to a diversified chemical/pharmaceutical company for a molecular biology-based diagnostic assay method.
• Exclusive license to a biotechnology company for an antisense therapeutic.
• Non-exclusive license for an immunoassay used in clinical laboratories.
• Exclusive license to a small biopharmaceutical company for a novel treatment for juvenile diabetes.
• Exclusive license to a biotechnology company for a novel cancer therapy.
• Non-exclusive license to a photodynamic therapy company for a method of treating a connective tissue disease.

Other Licenses: Medical Devices and Lasers

• Exclusive license to a device manufacturer for a laser-based device for use in endometrial and other surgery.
• Exclusive license to a start-up company for a laser-based technology for transcutaneous drug delivery, with follow-on sponsored research and option agreements with this company's successor.
• Exclusive license to a laboratory equipment manufacturer for a method to improve the efficiency of scintillation counting.
• Exclusive license to a manufacturer of X-ray equipment for mammography, for an improvement to a component of such equipment.
• Exclusive license to a start-up laser therapeutics company for a method of treating obstructions in blood vessels.

Sponsored Research Agreements

• Sponsored research agreement with a U.S./Europe-based multinational for research on mechanisms of pathogenesis, about $1 million per year for 4 years.
• Sponsored research agreement with a biotechnology company for vaccine research, $300,000 per year for 3 years.
• Sponsored research agreement with a biotechnology company relating to cancer screening techniques, $200,000 per year for two years.
• Sponsored research agreement with a multinational agrichemical company for research on disease resistance in plants, $250,000 per year for 3 years.
• Sponsored research with a pharmaceutical company relating to a novel anesthetic drug, $150,000 for one year.
  

Representing the Academic Side:

• McLean Hospital: exclusive license for a portfolio of patents for treatment of psychiatric disorders, to a European pharmaceutical company.
• McLean Hospital: Two major research collaborations in MRI imaging, as well as approximately 30 sponsored research and clinical trial agreements.
• McLean Hospital: License of a portfolio of patents for a diagnostic test methodology to a  new spin-off company.
• McLean Hospital: Option agreement and subsequent license agreement with a start-up company for a patented new therapeutic use for a known drug; two option agreements with a biotechnology company for therapeutic uses of natural product compounds.
• McLean Hospital: Two licenses of copyrighted patient survey forms to a pharmaceutical company.
• Joslin Diabetes Center: Collaboration and license agreement for a novel vaccine product.
• Joslin Diabetes Center: Several research tool/mouse model licenses to pharmaceutical and biotech companies.
• Joslin Diabetes Center: Approximately 20 sponsored research agreements with biotechnology and pharmaceutical companies, and one license amendment with a major pharmaceutical company and one with a biotechnology company.
•  Mass. General Hospital: License for an agricultural biotechnology tool; several sponsored research agreements including a major genomics/proteomics collaboration with a biotechnology company.
• Mass. General Hospital: Non-exclusive license to a research products company for a portfolio of gene expression patents.
• Mass. General Hospital: Currently negotiating a license with a major pharmaceutical company for a patented methodology to improve expression of therapeutic proteins.
•  Brigham and Women’s Hospital: License amendment for a medical device technology, to accommodate the licensee’s intended cross-license with another company; currently negotiating license agreement for a novel surgical device.

Representing the Industrial Side: 

• MTA and major license amendment for a nanotechnology start-up company with its founding university (Tufts University).
• Option agreement with Tufts University for a spin-off company’s founding technology.
• Option and license agreements with the University of Georgia for the founding technology of Applied PhytoGenetics, Inc., including subsequent amendments.
• Collaboration agreements and sublicense agreements for Applied PhytoGenetics, Inc.
• Sublicense and collaboration agreement for Applied PhytoGenetics, Inc. with a Korean start-up company.
• Project-specific agreements for Applied PhytoGenetics, Inc. to carry out feasibility studies of soil remediation technologies.
• Earlier in career, negotiated a partnering relationship between a European bioremediation company and a U.S. engineering firm, with respect to a technology for treatment of metals-contaminated water.